CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage
biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular
diseases, granted equity awards on January 31, 2018, that were previously approved by the Compensation Committee of its Board of
Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to twenty individuals
hired by Sarepta in January 2018. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 92,793 shares of Sarepta's common stock. The options have an
exercise price of $65.54 per share, which is equal to the closing price of Sarepta's common stock on January 31, 2018. One-fourth
of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter
1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to
each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such
employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision
genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its
potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website
at www.sarepta.com. We encourage investors and potential investors to consult our
website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
iestepan@sarepta.com
or
W2O Group
Brian Reid, 212-257-6725
breid@w2ogroup.com
